• 
• 
• 
• 
  • Ogłoszenia
  • Plan wydawniczy
  • Regulamin ogłaszania prac
  • Zasady recenzowania i recenzenci
• 
• 
• 
• 

Wydanie 1/2013
str. 18

Skuteczność i bezpieczeństwo stosowania latanoprostu w leczeniu jaskry i nadciśnienia ocznego u dzieci – 5-letnie doświadczenia własne

Safety and Efficacy of Latanoprost in Glaucoma and Ocular Hypertension Treatment in Children – Five Year Experience

Magdalena Pilas-Pomykalska^1,2, Dorota Tomaszkiewicz-Mondry^1,2, Danuta Węgrzynowska^1,2, Janusz Czajkowski^3,4

¹ Klinika Okulistyki Instytutu „Centrum Zdrowia Matki Polki” w Łodzi
P.o. kierownika: dr n. med. Dorota Tomaszkiewicz-Mondry
² Centrum Okulistyki „Oko Dziecka” Sp. z o.o.
Kierownik: dr Danuta Węgrzynowska
³ II Katedra Ginekologii i Położnictwa Uniwersytetu Medycznego w Łodzi
Kierownik: prof. dr hab. n. med. Grzegorz Krasomski
⁴ Specjalistyczny Gabinet Okulistyczny „Oculo-Med” w Łodzi
Kierownik: prof. dr hab. n. med. Janusz Czajkowski

Summary: Purpose: To evaluate the safety and efficacy of prostaglandin analogue: latanoprost 0.005% (Xalatan) in various types of glaucoma and ocular hypertension (OH) in children between 10–18 years of age.
Material and Methods: Retrospective analysis of all patients between 10–18 years of age, with a diagnosis of glaucoma or ocular hypertension, who were treated with topical latanoprost at the Department of Ophthalmology and Outpatient Clinic of the Polish Mother’s Memorial Hospital Research Institute from year 2005 to 2010. Minimum follow-up time on latanoprost was 3 months. The baseline IOP was compared with the postlatanoprost IOP for each patient. Responders were defined as those who had at least 15% IOP reduction on treatment. Systemic and ocular side effects and any changes in ocular exam were noted at follow-up visits.
Results: 19 patients with a variety of glaucoma diagnoses (7 with juvenile glaucoma, 4 with congenital, 2 with infantile glaucoma, 3 with aphakic glaucoma, 1 with aniridia, 1 with glaucoma according to retinopathy of prematurity – ROP, 1 with Sturge-Weber syndrome) and 13 individuals with ocular hypertension who had interpretable IOP data were included in the study. The mean IOP reduction for glaucoma group after the addition of latanoprost was 9.35% (2.15 mmHg) and for OH group was 20.63% (4.95 mmHg). Nine patients from glaucoma group (47.3%) and ten patients from OH group (76.9%) were responders. No systemic side effects were reported and ocular side effects were infrequent and mild.
Conclusions: The systemic and ocular safety profile of latanoprost in children appeared to be excellent. Efficacy of latanoprost in pediatric patients depended on age and diagnosis. Older children responded to treatment more likely than younger ones. Latanoprost showed significant ocular hypotensive effect in patients with OH, juvenile open-angle glaucoma and in some children with aphakic glaucoma but was not effective in patients with congenital/infantile glaucoma, aniridia or ROP. Response to treatment varied individually even within a group of patients with the same diagnosis.

Słowa kluczowe: jaskra dziecięcia, nadciśnienie oczne, terapia jaskry, latanoprost, analogi prostaglandyn.

Keywords: pediatric glaucoma, ocular hypertension, glaucoma treatment, latanoprost, prostaglandin analogues.

powrót